interactive about myl dated Jan. 26. could k2b1 be blowing smoke again? wall st. journal did have a recent article favorable on generics and myl:
The Wall Street Journal -- January 19, 1998
Generic-Drug Firms Are Seen
Healthy Results for the Fourth
By Jennifer Fron Mauer
Dow Jones Newswires
NEW YORK -- Improved pricing, continued cost-cutting and new-drug
approvals helped boost fourth-quarter profits at most generic-drug makers.
After heavier-than-usual discounting in 1996, most of the companies kept
prices firmer last year, analysts said. David Saks, an analyst at Gruntal &
Co., said the discounting averaged 7% to 9% in 1997, compared with 15%
to 25% in 1996.
"Pricing is the best it's been in years," Mr. Saks added.
SBC Warburg Dillon Read & Co. analyst Jerry Treppel said earnings at
generic-drug companies also are benefiting from cost-cutting.
In addition, the industry has seen an increase in new-drug approvals. Mr.
Saks said the U.S. Food and Drug Administration approved 240 generic
drugs in 1997, up from 190 in 1996 and nearly twice the 122 it approved in
Only Ivax Corp., which is in the midst of a lengthy restructuring, is expected
to turn in a poor fourth-quarter performance. Analysts estimate the Miami
company's losses widened to 34 cents a share from two cents in fourth
quarter of 1996, according to estimates compiled by First Call Corp.
Mylan Laboratories Inc., of Pittsburgh, which just completed its fiscal third
quarter, is expected to earn 24 cents a share, up from 15 cents a year
earlier, First Call said. Independent analyst Hemant Shah said Mylan
continues to benefit from sales of its generic version of the ulcer-treatment
Watson Pharmaceutical Inc. of Corona, Calif., known for making narcotic
pain-killers, is seen earning 32 cents a share in the fourth quarter, compared
with a split-adjusted 26 cents a year earlier.
Israel's Teva Pharmaceutical Industries Ltd. is expected to earn 64 cents
per American depositary receipt, up from 43 cents, excluding a write-off, a
The biggest improvement is expected to come from Alpharma Inc. Analysts
estimate the Fort Lee, N.J., company earned 24 cents a share, compared
with a loss of 36 cents, excluding charges, a year earlier, First Call said.
With only a limited number of brand-name drugs coming off patent during
the next two years, analysts said, generic-drug makers are looking further
ahead. In the first years of the new century, makers of some of the nation's
best-known prescription drugs will lose their patents, exposing them to
competition from generic companies.
Mr. Saks predicted "2000 to 2003 will be boom time in Genericville."
However, he said, the expiration of patents is merely an opportunity.
Generic-drug companies must be prepared to exploit it when it comes, or
risk losing it altogether.
I don't know who k2b1 and octavious are trying to kid. They are
one and the same. Even their spellings and grammatical errors are alike. Some kind of broken english. But the perfect stock pickers...ha, ha.
he's just telling you what he thinks you want to hear.
have you ever planted a tree in the back yard? did you
go out measuring its growth every day? this week its at
18 feet but last week it was at 19.5 feet? very strange.
could it just be the wind blowing it a little? it won't
break. it is an oak. and it is still growing regardless
of what your little stick says today. we'll fall asleep for
six or eight months and go out back and it will be 28-30 feet
by then. listen. you can hear it growing. why keep digging
it up and replanting it? makes no sense.